Apheresis Related Complication
Conditions
Keywords
Children, therapeutic exchange, neuropediatric, immunoadsorption
Brief summary
After developing in pediatric hematology and nephrology, therapeutic apheresis is increasingly used in pediatric neurology despite a sparse level of evidence. There are a few retrospective series with a small number of patients, concerning mainly autoimmune diseases (encephalitis, myasthenia gravis, polyradiculoneuritis). The objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.
Detailed description
Multicenter medical data collection : * Montpellier * Toulouse * Bordeaux * Marseille * Nancy * Paris Kremlin Bicêtre * Paris Robert Debré * Paris Necker * Paris Trousseau * Lyon * Besançon * Rennes * Reims * Strasbourg * La Réunion * Nantes * Tours
Interventions
OTHEREfficacy of apheresis
Efficacy of apheresis
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children under 18. * Supported in a participating CHU between 2014 and 2019. * Having benefited from therapeutic apheresis (plasma exchanges and immunoadsorption) in a neuropediatric indication
Exclusion criteria
\- Family or patient refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| global neurological efficacy of therapeutic apheresis as assessed | through study completion, an average of 2 years | lobal neurological efficacy of therapeutic apheresis as assessed by modified rankin score Modifed Rankin score, ranging from 0 (no symptoms) to 6 (death) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of therapeutic apheresis adverse events as assessed | through study completion, an average of 2 years | tIncidence of therapeutic apheresis adverse events as assessed by low blood tension rate, transfusion rate, infection rate, hypocalcaemia rate, thrombosis rate, allergy rate, anemia rate, hemostasis disorders rate). |
| Incidence of adjuvant treatments | through study completion, an average of 2 years | Incidence of adjuvant treatments (corticosteroid therapy, immunoglobulins, immunosuppressants), |
| Incidence of hospitalization in intensive care | through study completion, an average of 2 years | Incidence of hospitalization in intensive care, intubation rate |
| Description of the therapeutic apharesis modalities | through study completion, an average of 2 years | number of procedures |
| Number of participitants with treatment-related adverse events | during procedures | rate of arterial hypotension (\< age standards and and requiring isotonic saline bolus, for each patient and for procedure) |
Countries
France
Outcome results
None listed